In summary, our study reveals that the IGFBP2/ITGA5 signaling pathway plays a crucial role in promoting resistance to gefitinib in NSCLC through the activation of STAT3/CXCL1 axis. This evidence concerns the gene ITGA5 and non-small cell lung carcinoma.